Brief: Bioxcel Therapeutics Announces Positive Topline Results
25/06/2024 12:01
June 25 (Reuters) - BioXcel Therapeutics Inc BTAI.O :
* BIOXCEL THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
POST-MARKETING REQUIREMENT STUDY EVALUATING PRN TREATMENT OF
IGALMI™ (DEXMEDETOMIDINE) SUBLINGUAL FILM FOR AGITATION
ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA
* BIOXCEL THERAPEUTICS INC: STUDY ACHIEVED ITS OBJECTIVE
* BIOXCEL THERAPEUTICS INC: STUDY DEMONSTRATED NO EVIDENCE
OF
TACHYPHYLAXIS, TOLERANCE, OR WITHDRAWAL WITH 180 MCG DOSE
Source text for Eikon: ID:nGNXn9HTr
Further company coverage: BTAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty